Amorcyte: Investor Presentation (Amorcyte) - Apr 18, 2013 - "Phase 1 Trial Results Summary"; "Dose Response Correlated with Mobile CD34+ Cells"; "Patients dosed ≥ the threshold dose of 10 million cells showed significant improvement in perfusion"; "DSMB determined that no adverse events were related to therapy"; "Increased doses of CD34+/SDF-1 mobile cells reduced the size of infarct region by CMR"; "Y= Δ Infarct % LV Mass, X = Dose of SDF1 mobile CD34+ cells"; "Increasing doses of CD34+/ SDF-1 mobile cells reduced RTSS indicating improved perfusion Y= Δ RTSS, X = Dose of SDF1 mobile CD34 cells"
P1 data • Acute Coronary Syndrome
|